A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT ID: NCT06770933
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
100 participants
INTERVENTIONAL
2025-02-11
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT06852963
CLN-0046: Treatment of AMD Subjects With OTX-TKI
NCT03630315
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
NCT07235085
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
NCT05697809
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 100 male and female subjects aged ≥ 18 years with a documented diagnosis of Type 1 Diabetic Mellitus or Type 2 Diabetic Mellitus with moderate to severe NPDR (without CI-DME) will be enrolled, if they meet all the eligibility criteria for the study.
Subjects will be randomized 1:1 to 1 of 2 study cohorts:
* Cohort 1 (n = 50): VX-01 (film-coated tablets, 150 mg administered BID)
* Cohort 2 (n = 50): Placebo (film-coated tablets, administered BID)
Subjects will be stratified by the presence or absence of proliferative diabetic retinopathy (PDR) and by glycated hemoglobin (HbA1c) of ≥ 8.5% or \< 8.5% at Screening. All subjects will take 1 tablet of VX-01 or placebo BID for 52 consecutive weeks. All subjects will be followed for 12 weeks after completion of treatment at Week 52.
The Sponsor, study site staff, monitors, personnel, and subjects will be masked to treatment assignment during the entirety of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VX-01
Cohort 1 will include 50 subjects who will be randomized to take investigational drug VX-01 (film-coated tablets) at dose of 150 mg, administered BID.
VX-01
There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.
Placebo
Cohort 2 will include 50 subjects who will be randomized to receive the placebo drug (film-coated tablets), that will be administered BID.
Placebo
Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VX-01
There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.
Placebo
Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must be aged \> 18 years at the time of Screening.
* Subject must have a body mass index (BMI) of between 18 and 40 kg/m2, inclusive.
* Subject has a documented diagnosis of T1DM or T2DM.
* Subject has moderate to severe NPDR, as determined by a Central Reading Centre (CRC) using DRSS in at least one eye
* Subject must have clear ocular media and be able to undergo adequate pupil dilation to allow adequate fundus imaging of both eyes.
* Female subject must be either:
1. Of non-childbearing potential: post-menopausal or documented surgically sterile post hysterectomy (at least 1 month prior to Screening)
2. Or, if of childbearing potential, must have a negative serum pregnancy test at Screening and must use 2 acceptable forms of contraception, starting at Screening and throughout the study period and for 28 days after the final IP administration.
* Female subject must not be breastfeeding at Screening or during the study period, and for 28 days after the final IP administration.
* Male subject must be surgically sterile (\> 30 days since vasectomy with no viable sperm), or if engaged in sexual relations with a female of childbearing potential, the couple should agree to use 2 acceptable contraceptive methods from Screening, during the study, and for 28 days after last IP administration.
Female subject must not donate ova or male subject must not donate sperm starting at Screening and throughout the study period, and for 28 days after the final IP administration.
* Subject must have Best Corrected Visual Acuity (BCVA) assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) protocol letters score of ≥ 70 letters in study eye, and ≥ 20 letters in the non-qualified fellow eye.
* Subject must have the ability, in the opinion of the Investigator, and willingness to return for all scheduled visits and perform all assessments.
* Subject agrees not to participate in another interventional study after signing the informed consent and until the End of Study (EOS) visit has been completed.
Exclusion Criteria
* Presence of CI-DME (with central subfield thickness \[CST\] measured greater than 325 μm on spectral domain optical coherence tomography \[SD-OCT\]) threatening the center of the macula (within 1,000 μm of the foveal center) in either eye, or presence of DME requiring treatment.
* Presence of moderate to high-risk PDR (DRSS level 65 or higher).
* Any prior treatment (in either eye) with:
1. Focal or grid laser photocoagulation within the past 6 months prior to Screening or pan-retinal photocoagulation (PRP) at any time.
2. Systemic or intravitreal anti-vascular endothelial growth factor (VEGF) agents within the last 12 months prior to Screening.
3. Intraocular, sub-tenon or periocular steroids, including triamcinolone and dexamethasone implant within the last 6 months, or suprachoroidal triamcinolone within the last 3 months prior to Screening.
4. Fluocinolone implant within the last 3 years prior to Screening.
5. Prior treatment for NPDR with any other treatment which is not labelled for NPDR within 1 year prior to Screening (e.g., calcium dobesilate, fibrate medication).
6. Vitrectomy at any timepoint prior to Screening.
7. Yttrium-Aluminium-Granate (YAG) capsulotomy within 3 months prior to Screening.
* Active uveitis, vitritis, or infection in either eye including infectious conjunctivitis, keratitis, scleritis, or endophthalmitis.
* History of corneal transplant and/or vitrectomy or any other ocular incisional surgery in either eye (e.g., shunt surgery). Note: Subjects who have had cataract or refractive surgery in either that was more than 3 months prior to Screening may be permitted at the discretion of the Investigator.
* Uncontrolled glaucoma, as evidenced by intraocular pressure (IOP) \> 25 mmHg despite up to 4 glaucoma medications, or evidence of glaucomatous visual field loss or has advanced glaucoma (e.g., prior shunt surgery) in either eye.
* Clinically significant ocular disease in either eye that in the opinion of the Investigator would preclude participation in the study.
* Presence of macular or retinal vascular disease including DME and/or retinopathy from causes other than diabetes, age-related macular degeneration, pattern dystrophy, choroidal neovascularisation of any cause, retinal vein occlusion, retinal artery occlusion in either eye.
* History of retinal detachment or full-thickness macular hole post intraocular surgery in either eye, or idiopathic or autoimmune uveitis in either eye.
* Any other ocular disease that may cause substantial reduction in BCVA.
Systemic:
* Known, suspected hypersensitivity or contraindication to IP.
* Uncontrolled diabetes mellitus with HbA1c of ≥ 12%.
* Initiation of treatment with glucagon-like peptide-1 (GLP-1) modulators for glycaemic control and other indications within the last 3 months prior to Screening.
* Initiation of intensive insulin treatment (a pump or multiple daily injections) within 3 months prior to Screening or plans to do so in the next 3 months.
* Current use of coumarin anticoagulants (Coumadin/Warfarin).
* On dialysis or an estimated glomerular filtration rate (eGFR) of \< 30 mL/min/1.73m2 as per CKD-EPI evaluation at Screening. (Active Diabetic Ketoacidosis or Hyperglycemic Hyperosmolar Nonketotic State).
* Hypertension with resting diastolic blood pressure (BP) \> 100 mmHg or systolic BP \> 180 mmHg on 2 consecutive measurements at least 5 minutes apart. Note: If the result is out of range, the assessment may be repeated once prior to randomisation for confirmation.
* Resting heart rate outside the specified range (50 to 110 beats per minute). Note: If the result is out of range, the assessment may be repeated once prior to randomisation for confirmation.
* History of chronic liver disease or presence of elevated (defined as \> 3 × upper limit of normal) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) consistent with such diagnosis.
* Known to be immunocompromised or receiving immunosuppressive therapy. Note: Subjects receiving low dose corticosteroids may be eligible, at the discretion of the Investigator.
* Currently receiving treatment with a strong inhibitor of the P-glycoprotein transporter (see Section 6.4.2), which may interfere with the IP.
* History of allergy to fluorescein.
* Any disease or medical condition that in the opinion of the Investigator would interfere with the study, prevent the subject from successfully participating in the study, or which might confound the study results.
* Participation in any investigational study within 30 days prior to Screening or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion.
* History of blood transfusion or severe blood loss within 3 months prior to Screening, known hemoglobinopathy, and severe anaemia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vantage Biosciences Australia Pty Ltd
INDUSTRY
Vantage Biosciences Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Stanford Byers Eye Institute
Palo Alto, California, United States
California Retina Consultants- Santa Barbara
Santa Barbara, California, United States
Florida Retina Institute - Jacksonville Southside
Jacksonville, Florida, United States
Retina Associates
Elmhurst, Illinois, United States
Cumberland Valley Retina Consultants
Hagerstown, Maryland, United States
Erie Retina Research
Erie, Pennsylvania, United States
Piedmont Eye Center
Lynchburg, Virginia, United States
Eye Clinic Albury Wodonga
Albury, New South Wales, Australia
Retina And Eye Consultants Hurstville
Hurstville, New South Wales, Australia
Marsden Eye Specialists
Parramatta, New South Wales, Australia
Sydney Eye Hospital
Sydney, New South Wales, Australia
Sydney Retina Clinic
Sydney, New South Wales, Australia
Sydney West Retina
Westmead, New South Wales, Australia
University of the Sunshine Coast Clinical Trials (Birtinya)
Birtinya, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Prince of Wales Hospital The Chinese University of Hong Kong
Shatin, , Hong Kong
HKU Eye Centre
Wong Chuk Hang, , Hong Kong
University Malaya Medical Centre
Petaling Jaya, Kuala Lumpur Federal Territory of Kuala Lumpur, Malaysia
Hospital Pulau Pinang
George Town, Pulau Pinang, Malaysia
Hospital Shah Alam
Shah Alam, Selangor, Malaysia
Hospital Al-sultan Abdullah Uitm
Sungai Buloh, Selangor, Malaysia
Hospital Selayang
Selayang Baru Utara, , Malaysia
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX01-DR-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.